Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial

被引：167

作者：

Huober, J. ^{[1
,5
]}

Fasching, P. A. ^{[2
,14
]}

Barsoum, M. ^{[3
]}

Petruzelka, L. ^{[4
]}

Wallwiener, D. ^{[5
]}

Thomssen, C. ^{[6
]}

Reimer, T. ^{[7
]}

Paepke, S. ^{[8
]}

Azim, H. A. ^{[9
]}

Ragosch, V. ^{[10
]}

Kubista, E. ^{[11
]}

Baumgaertner, A. K. ^{[8
]}

Beckmann, M. W. ^{[2
]}

May, C. ^{[12
]}

Nimmrich, I. ^{[12
]}

Harbeck, N. ^{[8
,13
]}

机构：

[1] Kantonsspital, Breast Ctr, CH-9007 St Gallen, Switzerland

[2] Univ Erlangen Nurnberg, Dept Gynaecol, D-91054 Erlangen, Germany

[3] Cairo Univ, Natl Canc Inst, Cairo, Egypt

[4] Univ Hosp Prague, Dept Oncol, Prague, Czech Republic

[5] Univ Tubingen, Dept Obstet & Gynaecol, Tubingen, Germany

[6] Univ Halle Wittenberg, Dept Gynaecol, Halle, Saale, Germany

[7] Univ Rostock, Dept Obstet & Gynaecol, Rostock, Germany

[8] Tech Univ Munich, Frauenklin Rechts Isar, Munich, Germany

[9] Cairo Univ, Fac Med, Dept Clin Oncol, Cairo, Egypt

[10] Asklepios Klin Altona, Dept Gynaecol, Hamburg, Germany

[11] Med Univ Vienna, Dept Gynaecol, Vienna, Austria

[12] Novartis Pharrna GmbH BU Oncol, Nurnberg, Germany

[13] Univ Cologne, Breast Ctr, Dept OB&GYN, D-50931 Cologne, Germany

[14] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA

来源：

BREAST | 2012年 / 21卷 / 01期

关键词：

Metastatic breast cancer; Endocrine treatment; Letrozole; Trastuzumab; ADJUVANT CHEMOTHERAPY; ESTROGEN-RECEPTOR; ENDOCRINE THERAPY; TAMOXIFEN; HER-2/NEU; ARIMIDEX; SAFETY; PLUS; HER2;

D O I：

10.1016/j.breast.2011.07.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The eLEcTRA trial compared efficacy and safety of letrozole combined with trastuzumab to letrozole alone in patients with HER2 and hormone receptor (HR) positive metastatic breast cancer (MBC). Patients were randomized to either letrozole alone (arm A, n = 31) or letrozole plus trastuzumab (arm B, n = 26) as first-line treatment. Additional 35 patients with HER2 negative and HR positive tumors received letrozole alone (arm C). Median time to progression in arm A was 3.3 months compared to 14.1 months in arm B (hazard ratio 0.67; p = 0.23) and 15.2 months in arm C (hazard ratio 0.71; p = 0.03). Clinical benefit rate was 39% for arm A compared to 65% in arm B (odds ratio 2.99, 95% CI 1.01-8.84) and 77% in arm C (odds ratio 5.34, 95% CI 1.83-15.58). The eLEcTRA trial showed that the combination of letrozole and trastuzumab is a safe and effective treatment option for patients with HER2 positive and HR positive MBC. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：27 / 33

页数：7

共 50 条

[41] Interim safety and efficacy analysis of phase IB/II clinical trial of tucatinib, palbociclib and letrozole in patients with hormone receptor and HER2-positive metastatic breast cancer
Shagisultanova, Elena
Gradishar, William
Brown-Glaberman, Ursa
Chalasani, Pavani
Brenner, Andrew J.
Stopeck, Alison
Mayordomo, Jose
Diamond, Jennifer R.
Kabos, Peter
Borges, Virginia F.
CANCER RESEARCH, 2021, 81 (04)
[42] Efficacy and safety of camrelizumab in combination with trastuzumab and chemotherapy as the first-line treatment for patients with HER2-positive advanced gastric cancer
Xu, Mengli
Meng, Xiangrui
Lu, Yao
Wang, Feng
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (02) : 548 - 558
[43] Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer
Crown, J.
Kennedy, M. J.
Tresca, P.
Marty, M.
Espie, M.
Burris, H. A.
DeSilvio, M.
Lau, M. R.
Kothari, D.
Koch, K. M.
Dieras, V.
ANNALS OF ONCOLOGY, 2013, 24 (08) : 2005 - 2011
[44] A Q-TWiST analysis of lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive (HR plus ) metastatic breast cancer (MBC)
Sherrill, B.
Amonkar, M.
Sherif, B.
Maltzman, J.
O'Rourke, L.
Johnston, S.
EJC SUPPLEMENTS, 2009, 7 (02): : 275 - 275
[45] Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results
Perez, Edith A.
Manuel Lopez-Vega, Jose
Petit, Thierry
Zamagni, Claudio
Easton, Valerie
Kamber, Julia
Restuccia, Eleonora
Andersson, Michael
BREAST CANCER RESEARCH, 2016, 18
[46] Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results
Edith A. Perez
José Manuel López-Vega
Thierry Petit
Claudio Zamagni
Valerie Easton
Julia Kamber
Eleonora Restuccia
Michael Andersson
Breast Cancer Research, 18
[47] Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
Wardley, Andrew M.
Pivot, Xavier
Morales-Vasquez, Flavia
Zetina, Luis M.
Dias Gaui, Maria de Fatima
Reyes, Douglas Otero
Jassem, Jacek
Barton, Claire
Button, Peter
Hersberger, Veronica
Torres, Antonio Anton
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 976 - 983
[48] Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
Lee, Yong-Pyo
Lee, Min-Sang
Kim, HongSik
Kim, Ji-Yeon
Ahn, Jin Seok
Im, Young-Hyuck
Park, Yeon Hee
CANCER RESEARCH AND TREATMENT, 2022, 54 (04): : 1130 - 1137
[49] Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China
Wang, Hao
Wang, Ye
Gong, Ruixue
Geng, Yuyu
Li, Li
ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (11) : 11382 - 11393
[50] Pertuzumab: A Review of Its Use for First-Line Combination Treatment of HER2-Positive Metastatic Breast Cancer
Paul L. McCormack
Drugs, 2013, 73 : 1491 - 1502

← 1 2 3 4 5 →